Team Name

代表论文 (*通讯作者)：

  1. Sui F, Chen P, Feng C, Yang Q, Zhang SQ, Ji M, Wang Y, Guan H*, Xing M*, Hou P*. A Feedback loop Involving Exosomal MiR-146a and NG2 to Propel the Development and Progression of Hypothyroidism. Thyroid. 2023;33(9):1064-1077.(IF: 6.6)

  2. Ren X, Feng C, Wang Y, Chen P, Wang S, Wang J, Cao H, Li Y*, Ji M*, Hou P*. SLC39A10 promotes malignant phenotypes of gastric cancer cells by activating CK2-mediated MAPK/ERK and PI3K/AKT pathways. Exp Mol Med. 2023;55(8):1757-1769.  (IF: 12.153)

  3. Yang Q, Dang H, Liu J, Wang X, Wang J, Lan X, Ji M*, Xing M*, Hou P*. Hypoxia switches TET1 from being tumor-suppressive to oncogenic. Oncogene. 2023; 42(20):1634-8. (IF: 8.756)

  4. Zeng Z, Zheng W, Hou P*. The role of drug-metabolizing enzymes in synthetic lethality of cancer. Pharmacol Ther. 2022; 240:108219. (IF: 13.4)

  5. Zheng W, Zeng Z, Lin S, Hou P*. Revisiting potential value of antitumor drugs in the treatment of COVID-19. Cell Biosci. 2022; 12(1):165. (IF: 9.548)

  6. Ma S, Wang N, Liu R, Zhang R, Dang H, Wang Y, Wang S, Zeng Z, Ji M*, Hou P*. ZIP10 is a negative determinant for anti-tumor effect of mannose in thyroid cancer by activating phosphate mannose isomerase. J Exp Clin Cancer Res. 2021; 40(1):387. (IF: 12.658) 

  7. Da C, Pu J, Liu Z, Wei J, Qu Y, Wu Y, Shi B, Yang J*, He N*, Hou P*. HACE1-mediated NRF2 activation causes enhanced malignant phenotypes and decreased radiosensitivity of glioma cells. Signal Transduct Target Ther. 2021; 6(1):399. (IF: 38.104)

  8. Su X, Feng C, Wang S, Shi L, Gu Q, Zhang H, Lan X, Zhao Y, Qiang W, Ji M*, Hou P*. The noncoding RNAs SNORD50A and SNORD50B-mediated TRIM21-GMPS interaction promotes the growth of p53 wild-type breast cancers by degrading p53. Cell Death Differ. 2021;28(8):2450-2464. (IF: 12.067)

  9. Wang S, Zhou X, Zeng Z, Sui M, Chen L, Feng C, Huang C, Yang Q, Ji M, Hou P*. Atovaquone-HSA nano-drugs enhance the efficacy of PD-1 blockade immunotherapy by improving hypoxic tumor microenvironment. J Nanobiotechnology. 2021;19(1):302. (IF: 10.2)

  10. Wu Y, Shi L, Zhao Y, Chen P, Cui R, Ji M, He N, Wang M*, Li G*, Hou P*. Synergistic activation of mutant TERT promoter by Sp1 and GABPA in BRAF V600E-driven human cancers. NPJ Precis Oncol. 2021 Jan 22;5(1):3. (IF: 10.092)

  11. Bai Z, Qu Y, Shi L, Li X, Yang Z, Ji M*, Hou P*. Identification of a germline CSPG4 variation in a family with neurofibromatosis type 1-like phenotype. Cell Death Dis. 2021; 12(8):765. (IF: 9.685)

  12. Li Y#, Su X#, Feng C, Liu S, Guan H, Sun Y, He N*, Ji M*, Hou P*. CYP2S1 is a synthetic lethal target in BRAF V600E-driven thyroid cancers. Signal Transduct Target Ther. 2020;5(1):191. (IF: 38.104)

  13. He W#, Yan J#, Li Y, Yan S, Wang S, Hou P*, Lu W*. Resurrecting a p53 peptide activator - An enabling nanoengineering strategy for peptide therapeutics. J Control Release. 2020;325:293-303. (IF: 11.467)

  14. Li M#, Ruan B#, Wei J, Yang Q, Chen M, Ji M*, Hou P*. ACYP2 contributes to malignant progression of glioma through promoting Ca 2+ efflux and subsequently activating c-Myc and STAT3 signals. J Exp Clin Cancer Res. 2020;39(1):106. (IF: 12.658)

  15. Wang N, Li Y, Wei J, Pu J, Liu R, Yang Q, Guan H, Shi B, Hou P*, Ji M*. TBX1 Functions as a Tumor Suppressor in Thyroid Cancer Through Inhibiting the Activities of the PI3K/AKT and MAPK/ERK Pathways. Thyroid. 2019; 29(3):378-394. (IF: 6.6)

  16. Su X#, Shen Z#, Yang Q, Sui F, Pu J, Ma J, Ma S, Yao D, Ji M*, Hou P*. Vitamin C kills thyroid cancer cells through ROS-dependent inhibition of MAPK/ERK and PI3K/AKT pathways via distinct mechanisms. Theranostics. 2019; 9(15):4461-4473. (IF: 11.6)

  17. Yang Q, Jiang W, Hou P*. Emerging role of PI3K/AKT in tumor-related epigenetic regulation. Semin Cancer Biol. 2019;59:112-124. (IF: 17.012)

  18. He W#, Yan J#, Wang L, Lei B, Hou P*, Lu W*, Ma PX*. A lanthanide-peptide-derived bacterium-like nanotheranostic with high tumor-targeting, -imaging and -killing properties. Biomaterials. 2019; 206:13-24. (IF: 15.304)

  19. He W#, Wang S#, Yan J#, Qu Y, Jin L, Sui F, Li Y, You W, Yang G, Yang Q, Ji M, Liu M, Shao Y, Ma PX*, Lu W*, Hou P*. Self-Assembly of Therapeutic Peptide into Stimuli-Responsive Clustered Nanohybrids for Cancer-Targeted Therapy. Adv Funct Mater. 2019; 29(10):1807736. (IF: 19.924)

  20. Dang S, Zhou J, Chen Y, Chen P, Ji M, Shi B, Yang Q*, Hou P*. Dynamic expression of ZNF382 and its tumor-suppressor role in hepatitis B virus-related hepatocellular carcinogenesis. Oncogene. 2019; 38(24):4804-4819. (IF: 8.756)

  21. Bian Z#, Yan J#, Wang S#, Li Y, Guo Y, Ma B, Guo H, Lei Z, Yin C, Zhou Y, Liu M, Tao K*, Hou P*, He W*. Awakening p53 in vivo by D-peptides-functionalized ultra-small nanoparticles: Overcoming biological barriers to D-peptide drug delivery. Theranostics. 2018; 8(19):5320-5335. (IF: 11.6)

  22. Li H, Tian Z, Qu Y, Yang Q, Guan H, Shi B, Ji M*, Hou P*. SIRT7 promotes thyroid tumorigenesis through phosphorylation and activation of Akt and p70S6K1 via DBC1/SIRT1 axis. Oncogene. 2019; 38(3):345-359. (IF: 8.756)

  23. He W#,*, Yan J#, Sui F#, Wang S, Su X, Qu Y, Yang Q, Guo H, Ji M, Lu W, Shao Y*, Hou P*. Turning a Luffa Protein into a Self-Assembled Biodegradable Nanoplatform for Multitargeted Cancer Therapy. ACS Nano. 2018;12(11):11664-11677. (IF: 18.027)

  24. He W#, Yan J#, Jiang W#, li S, Qu Y, Niu F, Yan Y, Sui F, Wang S, Zhou Y, Jin L, Ji M, Ma PX, Liu M*, lu W*, Hou P*. Peptide-Induced Self-Assembly of Therapeutics into a Well-Defined Nanoshell with Tumor-Triggered Shape and Charge Switch. Chem Mater. 2018; 30: 7034-46. (IF: 10.508)

  25. Li Y, Li X, Pu J, Yang Q, Guan H, Ji M, Shi B*, Chen M*, Hou P*. c-Myc is a major determinant for antitumor activity of Aurora A kinase inhibitor MLN8237 in thyroid cancer. Thyroid. 2018; 28:1642-54. (IF: 6.6)

  26. Li Y, Yang Q, Guan H, Shi B, Ji M, Hou P*. ZNF677 Suppresses Akt Phosphorylation and Tumorigenesis in Thyroid Cancer. Cancer Res. 2018;78(18):5216-5228. (IF: 13.312)

  27. Qu Y, Shi B, Hou P*. Activated ERK: An Emerging Player in miRNA Downregulation. Trends in Cancer. 2017;3(3):163-165. (IF: 19.161)

  28. Qu Y, Yang Q, Liu J, Shi B, Ji M, Li G, Hou P*. c-Myc is required for BRAFV600E-induced epigenetic silencing by H3K27me3 in tumorigenesis. Theranostics. 2017; 7(8):2092-2107. (IF: 11.6)

  29. Yang Q and Hou P*. Targeting PFKFB3 in the Endothelium for Cancer Therapy. Trends Mol Med. 2017;23(3):197-200. (IF: 15.272)

  30. Shi J, Qu Y, Li X, Sui F, Yao D, Yang Q, Shi B, Ji M, Hou P*. Increased expression of EHF via gene amplification contributes to the activation of HER family signaling and associates with poor survival in gastric cancer. Cell Death Dis. 2016;7(10):e2442. (IF: 9.685)

  31. Zhang Y, Sui F, Ma J, Ren X, Guan H, Yang Q, Shi J, Ji M, Shi B, Sun Y, Hou P*. Positive Feedback Loops between NrCAM and Major Signaling Pathways Contribute to Thyroid Tumorigenesis. J Clin Endocrinol Metab. 2017;102(2):613-24. (IF: 6.134)

  32. Qiang W, Zhao Y, Yang Q, Liu W, Guan H, Lv S, Ji M, Shi B, Hou P*. ZIC1 Is Putative Tumor Suppressor in Thyroid Cancer by Modulating Major Signaling Pathways and Transcription Factor FOXO3a. J Clin Endocrinol Metab. 2014; 99(7):E1163-72.(IF: 6.134)

  33. Cui B, Yang Q, Guan H, Shi B, Hou P*, Ji M*. PRIMA-1, a Mutant p53 Reactivator, Restores the Sensitivity of TP53 Mutant-type Thyroid Cancer Cells to the Histone Methylation Inhibitor 3-Deazaneplanocin A (DZNep). J Clin Endocrinol Metab. 2014; 99(6):E962-70. (IF: 6.134)

  34. Yang Q, Ji M, Guan H, Shi B, Hou P*. Shikonin Inhibits Thyroid Cancer Cell Growth and Invasiveness through Targeting Major Signaling Pathways. J Clin Endocrinol Metab. 2013; 98(12):E1909-17. (IF: 6.134)

  35. Qu Y, Dang S, Hou P*. Gene methylation in gastric cancer. Clin Chim Acta. 2013; 424:53-65. (IF: 6.314; ESI高被引)

  36. Hou P, Bojdani E, Xing M*. Induction of Thyroid Gene Expression and Radioiodine Uptake in Thyroid Cancer Cells by Targeting Major Signaling Pathways. J Clin Endocrinol Metab. 2010; 95(2):820-8. (IF: 6.134)

  37. Wang Y#, Hou P#, Yu H, Wang W, Ji M, Zhao S, Yan S, Sun X, Liu D, Shi B, Zhu G, Condouris S, Xing M*. High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors. J Clin Endocrinol Metab. 2007; 92(6):2387-90. (IF: 6.134) 

  38. Hou P, Liu D, Shan Y, Hu S, et al. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res. 2007; 13(4):1161-70. (IF: 13.801)

  39. Hou P, Liu D, Xing M*. The T1790A BRAF mutation (L597Q) in childhood acute lymphoblastic leukemia is a functional oncogene. Leukemia. 2007; 21(10):2216-8. (IF: 12.883)

  40. Hou P*, Chen Z, Ji M, He N, Lu Z*. Real-time PCR assay for ultrasensitive quantification of DNA-binding proteins. Clin Chem. 2007; 53(4):581-6. (IF: 12.167)

  41. Hou P, Ji M, Li S, Lu Z*. Microarray-based approach for high-throughput genotyping of single-nucleotide polymorphisms with layer-by-layer dual-color fluorescence hybridization. Clin Chem. 2004; 50(10):1955-7. (IF: 12.167)

  42. Hou P, Ji M, Ge C, Shen J, Li S, He N, Lu Z*. Detection of methylation of human p16(Ink4a) gene 5'-CpG islands by electrochemical method coupled with linker-PCR. Nucleic Acids Res. 2003; 31(16):e92. (IF: 19.16)

      其它SCI论文请链接http://www.ncbi.nlm.nih.gov/pubmed/?term=peng+hou